Regenxbio Inc. (RGNX)

Nasdaq: RGNX · Biological Products, (No Diagnostic Substances) · Rockville, MD · filing with the SEC since 2013

Full chart Alerts Compare

Grade5.6

◀ Past 7.0● Present 5.4▶ Future 4.7

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$170M+104.5%

Net income-$194M+14.6%

Earnings per share$-3.76+18.1%

Operating cash flow-$124M+28.4%

Cash$34.5M-40.1%

Debtn/a

Shareholders’ equity$103M-60.4%

Shares, diluted51.6M+4.2%

Return on equity-188.7%

The recordfrom its filings

Filings in 202674

Newest filingNov 10 · SCHEDULE 13G

Annual reportMar 5, 2026

Quarterly reportNov 5, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$900,000

Insider buys, 12 months$900,000

Patents granted8

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $154MNet income -$175MCash from operations -$152Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 16, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 23, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Regenxbio Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Rockville, MD. License and Service was 92% of fiscal 2025 revenue.

Newest on the record

Large holder notice on Nov 10. Before it, quarterly report on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About RGNX

Regenxbio Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Rockville, MD. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $170 million and a loss of $194 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersRockville, MD

Business modelProduct business

ExchangeNasdaq

Filing since2013

Fiscal year endsDec 31

SEC number (CIK)1590877

Peers on fileVCEL, IBRX, ADPT, MAZE

Who runs it

Financial performance

In fiscal 2025 Regenxbio’s revenue was $170.4 million, up 104.5% from $83.33 million the year before. It made a net loss of $193.9 million.

Annual report, filed Mar 5, 2026.

Financial statements

The grade

Regenxbio grades 5.6 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past7.0

● Present5.4

▶ Future4.7

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton RGNX · research, not advice